Maximize your engagement with specialty providers and gain valuable insights on their perspectives through Cardinal Health’s Specialty Summits.
AstraZeneca’s lupus drug fails to meet goals; FDA expands investigation into heart drugs; Lilly names new head of Oncology.
Opdivo’s commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
Strategies for differentiating CAR-T therapies emerge in the early days of 2018, while competitors race to catch up with Novartis and Gilead.
Amazon, Berkshire Hathaway, and JPMorgan team up to form a healthcare company; Takeda’s Zika vaccine receives FDA fast-track status
FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Sanofi to buy Bioverativ for $11.6 billion; Celgene to acquire Juno for $9 billion; Teva to lay off more than 200 in Philadelphia
Celgene reportedly in talks to buy Juno; Novartis’ Kymriah receives fast-track reviews in U.S. and Europe; BI’s Gilotrif gets expanded approval in lung cancer